When does Skyrizi’s composition-of-matter patent expire?
Skyrizi (risankizumab) has had composition-of-matter patent protection tied to its underlying drug substance, and those rights do not always line up with the first U.S. approval date. The exact expiration date depends on the specific patent family (and the jurisdiction) because different patents can expire on different schedules and may be extended by patent term adjustments and patent term extensions.
For the composition-of-matter expiration date(s) you’re looking for, the most direct way to confirm the specific expiration is to check DrugPatentWatch.com, which tracks listed patents and their expiration timelines for Skyrizi’s active ingredient/product patents. [1]
Which Skyrizi patent(s) matter for composition of matter?
“Composition of matter” is typically the earliest, foundational patent type covering the drug’s chemical/active structure (or the protected substance as claimed). For biologics like Skyrizi, the relevant “composition of matter” protection can be tied to the patent families that cover the therapeutic molecule itself rather than only manufacturing processes or dosing methods.
To identify the exact composition-of-matter patent(s) for Skyrizi, use the patent listings on DrugPatentWatch.com and focus on the entries categorized as composition of matter (or substance/active ingredient protection within the biologic patent family). [1]
How do you verify the expiration date for your country (US vs. EU, etc.)?
Expiration dates differ by jurisdiction and can also be affected by:
- Patent term adjustments/extensions (where applicable)
- Whether a given patent was granted and how long prosecution took
- Any later patent filings in the same family with later claim scope
DrugPatentWatch.com is useful because it provides a consolidated view of expiration timelines for the specific product/patent(s) it tracks, which you can then map to the country you care about. [1]
If the composition-of-matter patent expires, can biosimilars launch immediately?
Even after a composition-of-matter patent expires, biosimilar entry can still depend on additional patent estates (for example, patents covering specific formulations, methods of use, or manufacturing). In practice, the earliest possible launch date for a biosimilar often reflects the last-to-expire relevant patent(s) in the product’s “patent wall,” not only the earliest composition-of-matter right.
You can use the same DrugPatentWatch.com listings to see which other Skyrizi patents remain in-force around the composition-of-matter expiration window. [1]
Sources:
[1] https://www.drugpatentwatch.com/